TELO on Nasdaq
Telomir Pharmaceuticals, Inc.
American pharmaceutical preparations company based in Tampa. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative expenses | $8.1M | $9.6M |
| Related party travel costs | $370.5K | |
| Research and development expenses | $2.4M | $2.2M |
| Total operating costs | $10.5M | $12.2M |
| Interest income | $125.6K | $48.0K |
| Interest expense | -$4.3M | |
| Net loss | -$10.4M | -$16.5M |
| Basic loss per share | -$0.33 | -$0.56 |
| Diluted loss per share | -$0.33 | -$0.56 |
| Basic weighted average common stock shares outstanding | 31.7M shares | 29.5M shares |
| Diluted weighted average common stock shares outstanding | 31.7M shares | 29.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash | $7.3M | $1.3M | ||
| Prepaid expenses | $54.7K | $57.9K | ||
| Total current assets | $7.3M | $1.3M | ||
| Total assets | $7.3M | $1.3M | ||
| Trade accounts payable and accrued liabilities | $536.8K | $587.5K | ||
| Due to officer | $155.5K | |||
| Accrued compensation - officer | $417.5K | |||
| Due to related parties | $318.2K | $93.4K | ||
| Total current liabilities | $1.4M | $681.0K | ||
| Total liabilities | $1.4M | $681.0K | ||
| Additional paid-in capital | $46.9M | $31.2M | ||
| Accumulated deficit | -$41.0M | -$30.6M | ||
| Total stockholders equity | $5.9M | $643.0K | $3.4M | |
| Total liabilities and stockholders equity | $7.3M | $1.3M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 34.4M shares | 29.8M shares | ||
| Common stock, shares outstanding | 34.4M shares | 29.8M shares |
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash | $7.3M | $1.3M | ||
| Prepaid expenses | $54.7K | $57.9K | ||
| Total current assets | $7.3M | $1.3M | ||
| Total assets | $7.3M | $1.3M | ||
| Trade accounts payable and accrued liabilities | $536.8K | $587.5K | ||
| Due to officer | $155.5K | |||
| Accrued compensation - officer | $417.5K | |||
| Due to related parties | $318.2K | $93.4K | ||
| Total current liabilities | $1.4M | $681.0K | ||
| Total liabilities | $1.4M | $681.0K | ||
| Additional paid-in capital | $46.9M | $31.2M | ||
| Accumulated deficit | -$41.0M | -$30.6M | ||
| Total stockholders equity | $5.9M | $643.0K | $3.4M | |
| Total liabilities and stockholders equity | $7.3M | $1.3M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 34.4M shares | 29.8M shares | ||
| Common stock, shares outstanding | 34.4M shares | 29.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$10.4M | -$16.5M |
| Stock-based compensation expense | $5.3M | $6.9M |
| Issuance of common stock for services | $840.0K | |
| Credit loss expenses - loan due from related party | $130.0K | |
| Amortization of debt issuance costs | $4.3M | |
| Prepaid expenses | $3.2K | -$57.2K |
| Trade accounts payable and accrued liabilities | -$50.8K | $183.6K |
| Due to related parties | $224.8K | |
| Accrued compensation - officer | $417.5K | |
| Net cash used in operating activities | -$3.7M | -$5.1M |
| Payments under related party line of credit | -$101.0K | |
| Repayments to related party | -$433.9K | |
| Repayment from officer | $155.5K | |
| Proceeds from warrant exercise | $37.3K | |
| Proceeds from sale of common stock, related party | $3.0M | |
| Net proceeds from sale of common stock | $6.6M | $6.8M |
| Net cash provided by financing activities | $9.7M | $6.3M |
| Net change in cash | $6.0M | $1.3M |
| Deferred offering costs charged to additional paid-in capital | $303.3K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Telomir Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
- Chief executive officerErez Aminov Aug 15, 2024 to now8
- ChairErez Aminov Aug 15, 2024 to now8
- Chief financial officerAndriy Mushak Jun 9, 2026 to now9
- Chief financial officerAlan Weichselbaum Jun 10, 2025 to Jun 9, 202610
- Chief financial officerNathen Fuentes Feb 8, 2024 to Feb 8, 202411
- Chief financial officerMichelle Yanez Aug 29, 2024 to Sep 4, 202412
Board members and other officers (8)
- Board memberBradley Kroenig Feb 8, 2024 to Feb 8, 202413
- Board memberChristos Nicholoudis Feb 8, 2024 to Feb 8, 202414
- Board memberCraig Eagle Feb 8, 2024 to Feb 8, 202415
- Board memberMichael Allen Jerman Feb 8, 2024 to Aug 29, 202416
- Board memberTalhia Tuck Feb 8, 2024 to Feb 8, 202417
- Board memberEdward Clouston Macpherson Aug 15, 2024 to now18
- Board memberMatthew Pratt Whalen Aug 15, 2024 to now19
- General counselChristos Nicholoudis Feb 8, 2024 to Feb 8, 202414
Named in SEC Form D filings
People the company listed in its private-offering notices.
- President, Chief Executive Officer and ChairmanChris Chapman named Apr 3, 202320
- Treasurer, Chief Financial Officer and SecretaryJames McNulty named Apr 3, 202320
- DirectorDavid Vorhoff named Apr 3, 202320
- DirectorHugh McColl named Apr 3, 202320
- DirectorJude Uzonwanne named Apr 3, 202320
- DirectorTuck Talhia named Apr 3, 202320
Timeline
- Aug 15, 2024New chief executive Erez Aminov becomes CEO8
Filings
146 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 63 major events, 35 insider forms, 3 large holders, 1 private raises, 33 other. The latest 20:
- Oct 6, 20268-K EDGAR
- Sep 17, 20268-K EDGAR
- Sep 16, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Aug 19, 2026DEFA14A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Jul 28, 2026DEF 14A EDGAR
- Jul 27, 20264 EDGAR
- Jul 27, 20264 EDGAR
- Jul 27, 20264 EDGAR
- Jun 15, 20268-K EDGAR
- Jun 9, 20263 EDGAR
- Jun 8, 20268-K EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 22, 20264 EDGAR
- May 20, 20268-K EDGAR
The 146 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 1 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2024 | Aminov ErezCEO and Chairman | Sale | 400 | $6.11 | $2.4K | Form 4 |
| Feb 13, 2024 | McNulty Brian Patrick10% owner | Buy | 138,000 | $7.00 | $966.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- John Paul DejoriaSCHEDULE 13G/A, 3 filings Sep 18, 2025 to Aug 14, 202621
Money raised
Private offerings the company reported to the SEC on Form D.
- Mar 15, 2023Raised $1 million in a private offering of equity Form D: 10 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 33. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARErez Aminov, Chief executive officer
- 9
- 10
- 11
- 12
- 13SEC EDGARBradley Kroenig, Board member
- 14SEC EDGARChristos Nicholoudis, Board member
- 15SEC EDGARCraig Eagle, Board member
- 16SEC EDGARMichael Allen Jerman, Board member
- 17SEC EDGARTalhia Tuck, Board member
- 18
- 19SEC EDGARMatthew Pratt Whalen, Board member
- 20
- 21